The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol.
Creators: name: Ursprung, Stephan
name: Mossop, Helen
name: Gallagher, Ferdia
name: Sala, Evis
name: Skells, Richard
name: Sipple, Jamal AN
name: Mitchell, Thomas J
name: Chhabra, Anita
name: Fife, Kate
name: Matakidou, Athena
name: Young, Gemma
name: Walker, Amanda
name: Thomas, Martin G
name: Ortuzar, Mireia Crispin
name: Sullivan, Mark
name: Protheroe, Andrew
name: Oades, Grenville
name: Venugopal, Balaji
name: Warren, Anne
name: Stone, John
name: Eisen, Tim
name: Wason, James
name: Welsh, Sarah
name: Stewart, Grant
Publisher: name: Apollo - University of Cambridge Repository
Year: 2021
Subjects: Bayesian adaptive trial
Cediranib [MeSH]
Clear cell renal cell carcinoma [MeSH]
Clinical trial protocol [MeSH]
Durvalumab [MeSH]
Neoadjuvant therapy [MeSH]
Olaparib [MeSH]
Phase II clinical trial [MeSH]
Window-of-opportunity

description: BACKGROUND: Window-of-opportunity trials, evaluating the engagement of drugs with their biological target in the time period between diagnosis and standard-of-care treatment, can help prioritise promising new systemic treatments for later-phase clinical trials. Renal cell carcinoma (RCC), the 7th commonest solid cancer in the UK, exhibits targets for multiple new systemic anti-cancer agents including DNA damage response inhibitors, agents targeting vascular pathways and immune checkpoint inhibitors. Here we present the trial protocol for the WIndow-of-opportunity clinical trial platform for evaluation of novel treatment strategies in REnal cell cancer (WIRE). METHODS: WIRE is a Phase II, multi-arm, multi-centre, non-randomised, proof-of-mechanism (single and combination investigational medicinal product [IMP]), platform trial using a Bayesian adaptive design. The Bayesian adaptive design leverages outcome information from initial participants during pre-specified interim analyses to determine and minimise the number of participants required to demonstrate efficacy or futility. Patients with biopsy-proven, surgically resectable, cT1b+, cN0-1, cM0-1 clear cell RCC and no contraindications to the IMPs are eligible to participate. Participants undergo diagnostic staging CT and renal mass biopsy followed by treatment in one of the treatment arms for at least 14 days. Initially, the trial includes five treatment arms with cediranib, cediranib + olaparib, olaparib, durvalumab and durvalumab + olaparib. Participants undergo a multiparametric MRI before and after treatment. Vascularised and de-vascularised tissue is collected at surgery. A ≥ 30% increase in CD8+ T-cells on immunohistochemistry between the screening and nephrectomy is the primary endpoint for durvalumab-containing arms. Meanwhile, a reduction in tumour vascular permeability measured by Ktrans on dynamic contrast-enhanced MRI by ≥30% is the primary endpoint for other arms. Secondary outcomes include adverse events and tumour size change. Exploratory outcomes include biomarkers of drug mechanism and treatment effects in blood, urine, tissue and imaging. DISCUSSION: WIRE is the first trial using a window-of-opportunity design to demonstrate pharmacological activity of novel single and combination treatments in RCC in the pre-surgical space. It will provide rationale for prioritising promising treatments for later phase trials and support the development of new biomarkers of treatment effect with its extensive translational agenda. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03741426 / EudraCT: 2018-003056-21 .